Pfizer recently settled a decade-long case relating to its older treatments Celebrex and Bextra.
Assuming Pfizer’s settlement is in the range of related past settlements, there should be no long-term impact.
Considering Pfizer’s high dividend yield, solid balance sheet and strong forward outlook, we believe that dividend-focused investors don’t need to wait until it reports its second quarter earnings before buying.
Pfizer Settles Celebrex and Bextra Lawsuits. Pfizer (NYSE: